Pharmaceuticals
INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
NANJING, China and GAITHERSBURG, Md., Dec. 3, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation ("CDE") of the National Medical Products Adm...
2025-12-04 09:57
939
High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology
SUZHOU, China, Dec. 3, 2025 /PRNewswire/ -- On December 3, 2025 (local time in Arizona, USA), ImmVira Group ("ImmVira" or the "Company") announced a poster presentation at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025). The presentation featured the latest interim clinical...
2025-12-04 08:00
1041
ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting
Studies Demonstrate xCellSense® Platform's Ability to Predict Clinical Response
and Enable Patient Stratification for Drug Development.
PALO ALTO, Calif., Dec. 3, 2025 /PRNewswire/ -- ImpriMed
2025-12-04 01:00
1114
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
* FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL solution in a single-dose prefilled syringe for subcutaneous injection expands dosing flexibility and supports tailored treatment for individual patients with certain allergic diseases * OMLYCLO® (omalizumab-igec) is the first and only ...
2025-12-03 08:43
2104
Yuyu Pharma Announces Strategic Investment in Dalan Animal Health as Part of Accelerated Global Expansion in Animal Health
SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Yuyu Pharma announced today that it has completed a strategic investment in Dalan Animal Health, a U.S.-based biotechnology company advancing an innate immunity–based platform for developing vaccines for honeybees and shrimp. The investment marks a...
2025-12-02 22:00
2188
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
SYDNEY, Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity ...
2025-12-02 22:00
3125
Nature Communications | Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1
* AI Designs a Novel RPOTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its complex linker, demonstrating a powerful, end-to-end approach to new modality drug discovery. ...
2025-12-02 22:00
2407
GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper
* Officially recognized by WHO as a standard varicella vaccine strain alongside Oka * Interchangeability endorsed, enhancing global supply security YONGIN, South Korea, Dec. 2, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company, today announced that its propriet...
2025-12-02 13:00
1494
BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough
* Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma * The company enables seamless Europe–China tech transfer and faster biologics development through an integrated, end-to-end...
2025-11-28 21:00
1464
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
* Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors. * The collaboration includes precli...
2025-11-28 13:00
1395
Strategic Partnership | Sanyou Bio and Korea's FatiAbGen Join Forces to Expand the Global Biopharma Market
SHANGHAI, Nov. 27, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") andSouth Korea's FatiAbGen Co., Ltd. today jointly announced the signing of a comprehensive strategic collaboration agreement covering joint project development, exclusive representation in the K...
2025-11-27 22:00
1914
SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation
New addition strengthens SK Biopharmaceuticals' radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partnerships and value chain integration SEOUL, South Korea, Nov. 26, 2025 /PRNewswire/ -- SK Biopharmaceuticals, CO., Ltd., a biotech company specializing in ...
2025-11-27 10:39
1284
Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
* Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant Crohn's disease (CD) * Findings support the therapeutic potential of ZYMFENTRA in addressing ...
2025-11-26 14:48
2472
Renalys Pharma Announces Positive Topline Results from Phase III Study of Sparsentan in Japanese Patients with IgA Nephropathy
– In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine protein-to-creatinine ratio at Week 36, which was the study's primary endpoint, was -58.54%. Sparsentan was well-t...
2025-11-26 14:00
1143
BON Announced Next-Gen of Tea Pigment Digestive Health Products and Cooperation Agreement of US$26 Million with Beijing Huahai Keyuan
XI'AN, China, Nov. 25, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a non-exclusive cooperation agreement with Beijing Huahai Keyuan Technology Co...
2025-11-25 22:41
1209
Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population
SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...
2025-11-25 17:00
1484
HKeyBio Launches the HKEY-AIDMD 3.0--a Next-Generation Platform to Crack the Toughest Challenge in Autoimmune and Allergy Drug Development: Multi-target Combination Strategy Optimization
* The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection platf...
2025-11-25 00:30
1595
Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial
Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced onNovember 20 that it has administered the f...
2025-11-24 15:11
1033
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an u...
2025-11-24 08:01
1678
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
PISCATAWAY, N.J., Nov. 21, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the GenScript Biotech Global Forum London 2025 in the UK. This marks the Forum's second edition inEurope and the eighth consecutive G...
2025-11-22 06:32
2364
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 321 media titles]
2026-02-16 10:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Appier Delivers Record Results Driven by Agentic AI Innovation
[Picked up by 263 media titles]
2026-02-13 17:03Philips Evnia x SEGA: Elevating Immersion for YAKUZA KIWAMI 3 & DARK TIES | Unveiling the 27M2N6501L QD-OLED Monitor - Where Speed Meets Spectacle
[Picked up by 260 media titles]
2026-02-12 15:58
Most Read
Datasea Reports Second Fiscal Quarter 2026 Results
2026-02-12 22:20
8324
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
7498
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
2026-02-12 21:56
7065
